

Indian Immunologicals invests Rs 700 Cr in new vaccine manufacturing plant at Genome Valley

29 December 2023 | News

Expected to create more than 750 direct and indirect jobs

Indian Immunologicals Limited (IIL) has started construction of its new greenfield veterinary vaccine facility to manufacture the Foot and Mouth Disease Vaccine (FMD-Vac) as well as Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD+HS-Vac) in Hyderabad's Genome valley.

This brand-new unit will have a BSL3 facility for the manufacture of drug substances and a fill-finish capability for the production of both drug products FMD vaccine and the FMD+HS vaccine.

Telangana State Industrial Infrastructure Corporation Ltd (TSIIC), a Government of Telangana undertaking, had allotted the land to IIL at Biotech Park, Phase III, Karkapatla, Siddipet district in Telangana.

The proposed facility has a capacity of 150 million doses/annum of FMD vaccine or FMD+HS vaccine each. With an investment of approximately Rs 700 crore, the proposed facility is expected to create more than 750 direct and indirect jobs.

Dr K Anand Kumar, Managing Director, IIL said, "We are the largest supplier of FMD vaccine to Government of India's prestigious Livestock Health Disease Control Programme (LHDCP). We are in an exponential growth phase and expected to grow 40% this year alone. In order to sustain the momentum, IIL is seriously considering making additional investments in building infrastructure within India and in other emerging geographies including Africa in a manner to develop tools that will help in control and eradication of diseases."